{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:45:11Z","timestamp":1791229511919,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Huntington\u2019s disease (HD) is a rare, neurodegenerative disease and its complex motor, cognitive and psychiatric symptoms exert a lifelong clinical burden on both patients and their families.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To describe the clinical burden and natural history of HD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This longitudinal cohort study used data from the linked Swedish national registries to describe the occurrence of comorbidities (acute and chronic), symptomatic treatments and mortality in an incident cohort of individuals who either received the first diagnosis of HD above (adult onset HD; AoHD) or below (juvenile-onset HD; JoHD) 20\u00a0years of age, compared with a matched cohort\u00a0without HD from the general population. Disease burden of all individuals alive in Sweden was described during a single calendar year (2018), including the occurrence of key symptoms, treatments and hospitalizations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The prevalence of HD in 2018 was approximately 10.2 per 100,000. Of 1492 individuals with a diagnosis of HD during 2002 and 2018, 1447 had AoHD and 45 had JoHD. Individuals with AoHD suffered a higher incidence of obsessive\u2013compulsive disorder, acute psychotic episodes, pneumonia, constipation and fractures compared with matched controls. Individuals with JoHD had higher incidence rates of epilepsy, constipation and acute respiratory symptoms. Median time to all-cause mortality in AoHD was 12.1\u00a0years from diagnosis. Patients alive with HD in Sweden in 2018 displayed a pattern of increased clinical burden for a number of years since diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study demonstrates the significant and progressive clinical burden in individuals with HD and presents novel insights into the natural history of JoHD.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s00415-022-11418-y","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T02:02:35Z","timestamp":1666058555000},"page":"864-876","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Comorbidities and clinical outcomes in adult- and juvenile-onset Huntington\u2019s disease: a study of linked Swedish National Registries (2002\u20132019)"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7279-1812","authenticated-orcid":false,"given":"Hannah","family":"Furby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Lena","family":"Nordstroem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Lambrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Svenningsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5sa","family":"Peters\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"11418_CR1","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR et al (2015) Huntington disease. Nat Rev Dis Primers 1:15005","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"11418_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-5-40","volume":"5","author":"RA Roos","year":"2010","unstructured":"Roos RA (2010) Huntington\u2019s disease: a clinical review. Orphanet J Rare Dis 5(5):40","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"11418_CR3","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","volume":"89","author":"F Saudou","year":"2016","unstructured":"Saudou F, Humbert S (2016) The biology of huntingtin. Neuron 89(5):910\u2013926","journal-title":"Neuron"},{"issue":"4","key":"11418_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH et al (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10(4):204\u2013216","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"11418_CR5","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1136\/jnnp-2012-304636","volume":"84","author":"SJ Evans","year":"2013","unstructured":"Evans SJ, Douglas I, Rawlins MD, Wexler NS, Tabrizi SJ, Smeeth L (2013) Prevalence of adult Huntington\u2019s disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry 84(10):1156\u20131160","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"11418_CR6","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/cge.12574","volume":"89","author":"F Squitieri","year":"2016","unstructured":"Squitieri F, Griguoli A, Capelli G, Porcellini A, D\u2019Alessio B (2016) Epidemiology of Huntington disease: first post-HTT gene analysis of prevalence in Italy. Clin Genet 89(3):367\u2013370","journal-title":"Clin Genet"},{"key":"11418_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/mds.25717","volume":"29","author":"ER Fisher","year":"2014","unstructured":"Fisher ER, Hayden MR (2014) Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Mov Disord 29:105\u2013114","journal-title":"Mov Disord"},{"issue":"2","key":"11418_CR8","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000443738","volume":"46","author":"MD Rawlins","year":"2016","unstructured":"Rawlins MD, Wexler NS, Wexler AR, Tabrizi SJ, Douglas I, Evans SJ et al (2016) The prevalence of Huntington\u2019s disease. Neuroepidemiology 46(2):144\u2013153","journal-title":"Neuroepidemiology"},{"issue":"6","key":"11418_CR9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/brainsci10060340","volume":"10","author":"J Achenbach","year":"2020","unstructured":"Achenbach J, Thiels C, L\u00fccke T, Saft C (2020) Clinical manifestation of juvenile and pediatric HD patients: a retrospective case series. Brain Sci 10(6):340","journal-title":"Brain Sci"},{"issue":"2","key":"11418_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3233\/JHD-180339","volume":"8","author":"T Cronin","year":"2019","unstructured":"Cronin T, Rosser A, Massey T (2019) Clinical presentation and features of juvenile-onset Huntington\u2019s disease: a systematic review. J Huntingtons Dis 8(2):171\u2013179","journal-title":"J Huntingtons Dis"},{"issue":"14","key":"11418_CR11","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1002\/mds.25237","volume":"27","author":"LJ Cloud","year":"2012","unstructured":"Cloud LJ, Rosenblatt A, Margolis RL, Ross CA, Pillai JA, Corey-Bloom J et al (2012) Seizures in juvenile Huntington\u2019s disease: frequency and characterization in a multicenter cohort. Mov Disord 27(14):1797\u20131800","journal-title":"Mov Disord"},{"issue":"9","key":"11418_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3390\/brainsci10090575","volume":"10","author":"JL Schultz","year":"2020","unstructured":"Schultz JL, Moser AD, Nopoulos PC (2020) The association between CAG repeat length and age of onset of juvenile-onset Huntington\u2019s disease. Brain Sci 10(9):575","journal-title":"Brain Sci"},{"issue":"1","key":"11418_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/mds.28823","volume":"37","author":"HS Bakels","year":"2022","unstructured":"Bakels HS, Roos RAC, van Roon-Mom WMC, de Bot ST (2022) Juvenile-onset Huntington disease pathophysiology and neurodevelopment: a review. Mov Disord 37(1):16\u201324","journal-title":"Mov Disord"},{"key":"11418_CR14","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3389\/fneur.2019.00710","volume":"10","author":"AC Bachoud-Levi","year":"2019","unstructured":"Bachoud-Levi AC, Ferreira J, Massart R, Youssov K, Rosser A, Busse M et al (2019) International guidelines for the treatment of Huntington\u2019s disease. Front Neurol 10:710","journal-title":"Front Neurol"},{"issue":"6","key":"11418_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/brainsci7060067","volume":"7","author":"RA Paoli","year":"2017","unstructured":"Paoli RA, Botturi A, Ciammola A, Silani V, Prunas C, Lucchiari C et al (2017) Neuropsychiatric burden in Huntington\u2019s disease. Brain Sci 7(6):67","journal-title":"Brain Sci"},{"issue":"5","key":"11418_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2217\/nmt.11.45","volume":"1","author":"EA Epping","year":"2011","unstructured":"Epping EA, Paulsen JS (2011) Depression in the early stages of Huntington disease. Neurodegener Dis Manag 1(5):407\u2013414","journal-title":"Neurodegener Dis Manag"},{"issue":"1","key":"11418_CR17","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12883-019-1556-3","volume":"19","author":"C Ohlmeier","year":"2019","unstructured":"Ohlmeier C, Saum KU, Galetzka W, Beier D, Gothe H (2019) Epidemiology and health care utilization of patients suffering from Huntington\u2019s disease in Germany: real world evidence based on German claims data. BMC Neurol 19(1):318","journal-title":"BMC Neurol"},{"issue":"1","key":"11418_CR18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/acn3.51252","volume":"8","author":"L Ishihara","year":"2021","unstructured":"Ishihara L, Oliveri D, Wild EJ (2021) Neuropsychiatric comorbidities in Huntington\u2019s and Parkinson\u2019s Disease: a United States claims database analysis. Ann Clin Transl Neurol 8(1):126\u2013137","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"11418_CR19","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1111\/ene.13107","volume":"23","author":"C Jones","year":"2016","unstructured":"Jones C, Busse M, Quinn L, Dawes H, Drew C, Kelson M et al (2016) The societal cost of Huntington\u2019s disease: are we underestimating the burden? Eur J Neurol 23(10):1588\u20131590","journal-title":"Eur J Neurol"},{"issue":"1","key":"11418_CR20","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1080\/13696998.2021.2002579","volume":"24","author":"A Exuzides","year":"2021","unstructured":"Exuzides A, Reddy SR, Chang E, Ta JT, Patel AM, Paydar C et al (2021) Healthcare utilization and cost burden of Huntington\u2019s disease among medicare beneficiaries in the United States. J Med Econ 24(1):1327\u20131336","journal-title":"J Med Econ"},{"issue":"8","key":"11418_CR21","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3111\/13696998.2013.818545","volume":"16","author":"V Divino","year":"2013","unstructured":"Divino V, Dekoven M, Warner JH, Giuliano J, Anderson KE, Langbehn D et al (2013) The direct medical costs of Huntington\u2019s disease by stage. A retrospective commercial and Medicaid claims data analysis. J Med Econ 16(8):1043\u20131050","journal-title":"J Med Econ"},{"issue":"1","key":"11418_CR22","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1080\/13696998.2022.2033493","volume":"25","author":"E Shaw","year":"2022","unstructured":"Shaw E, Mayer M, Ekwaru P, McMullen S, Graves E, Wu JW et al (2022) Epidemiology and economic burden of Huntington\u2019s disease: a Canadian provincial public health system perspective. J Med Econ 25(1):212\u2013219","journal-title":"J Med Econ"},{"key":"11418_CR23","unstructured":"The Swedish National Patient Register. Available from: https:\/\/www.lupop.lu.se\/lupop-researchers\/population-data\/swedish-registers\/swedish-national-patient-register Accessed Sep 2022"},{"key":"11418_CR24","unstructured":"The Swedish National Prescribed Drug Register. Available from: https:\/\/www.lupop.lu.se\/lupop-researchers\/population-data\/swedish-registers\/swedish-prescribed-drug-register. Accessed Sep 2022"},{"key":"11418_CR25","unstructured":"Register TSCoD. Available from: https:\/\/www.lupop.lu.se\/lupop-researchers\/population-data\/swedish-registers\/swedish-cause-death-register#:~:text=The%20Swedish%20Cause%20of%20Death%20Register%20comprises%20data%20on%20all,Board%20of%20Health%20and%20Welfare. Sep 2022"},{"key":"11418_CR26","unstructured":"Etikpr\u00f6vningsmyndigheten. 2022"},{"key":"11418_CR27","unstructured":"The Swedish National Medical Birth Register. Available from: https:\/\/www.socialstyrelsen.se\/en\/statistics-and-data\/registers\/national-medical-birth-register\/. Accessed Sep 2022"},{"key":"11418_CR28","first-page":"1","volume":"1","author":"The Department for Registers and Statistics","year":"2022","unstructured":"The Department for Registers and Statistics (2022) The production and quality of the statistical register. Socialstyrelsen 1:1\u201324","journal-title":"Socialstyrelsen"},{"issue":"2","key":"11418_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1742-7843.2009.00494.x","volume":"106","author":"K Furu","year":"2010","unstructured":"Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT (2010) The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 106(2):86\u201394","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"11418_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/B978-0-12-801893-4.00006-7","volume":"144","author":"JS Paulsen","year":"2017","unstructured":"Paulsen JS, Miller AC, Hayes T, Shaw E (2017) Cognitive and behavioral changes in Huntington disease before diagnosis. Handb Clin Neurol 144:69\u201391","journal-title":"Handb Clin Neurol"},{"issue":"4","key":"11418_CR31","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/WNN.0000000000000171","volume":"31","author":"M Gagnon","year":"2018","unstructured":"Gagnon M, Barrette J, Macoir J (2018) Language disorders in Huntington disease: a systematic literature review. Cogn Behav Neurol 31(4):179\u2013192","journal-title":"Cogn Behav Neurol"},{"issue":"1","key":"11418_CR32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/jnnp.2008.147793","volume":"80","author":"ME Busse","year":"2009","unstructured":"Busse ME, Wiles CM, Rosser AE (2009) Mobility and falls in people with Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 80(1):88\u201390","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"11418_CR33","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/mds.22003","volume":"23","author":"YAM Grimbergen","year":"2008","unstructured":"Grimbergen YAM, Knol MJ, Bloem BR, Kremer BPH, Roos RAC, Munneke M (2008) Falls and gait disturbances in Huntington\u2019s disease. Mov Disord 23(7):970\u2013976","journal-title":"Mov Disord"},{"issue":"8","key":"11418_CR34","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s00701-016-2845-x","volume":"158","author":"JO Sipil\u00e4","year":"2016","unstructured":"Sipil\u00e4 JO, Posti JP, Majamaa K (2016) Chronic subdural hematomas in Finnish patients with Huntington\u2019s disease. Acta Neurochir (Wien) 158(8):1487\u20131490","journal-title":"Acta Neurochir (Wien)"},{"issue":"3","key":"11418_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3233\/JHD-170280","volume":"7","author":"J Kobal","year":"2018","unstructured":"Kobal J, Matej K, Ko\u017eelj M, Podnar S (2018) Anorectal dysfunction in presymptomatic mutation carriers and patients with Huntington\u2019s disease. J Huntingtons Dis 7(3):259\u2013267","journal-title":"J Huntingtons Dis"},{"issue":"7","key":"11418_CR36","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1342::AID-CNCR33>3.0.CO;2-3","volume":"86","author":"SA Sorensen","year":"1999","unstructured":"Sorensen SA, Fenger K, Olsen J (1999) Significantly lower incidence of cancer among patients with Huntington disease: an apoptotic effect of an expanded polyglutamine tract? Cancer 86(7):1342\u20131346","journal-title":"Cancer"},{"issue":"6","key":"11418_CR37","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S1470-2045(12)70132-8","volume":"13","author":"J Ji","year":"2012","unstructured":"Ji J, Sundquist K, Sundquist J (2012) Cancer incidence in patients with polyglutamine diseases: a population-based study in Sweden. Lancet Oncol 13(6):642\u2013648","journal-title":"Lancet Oncol"},{"issue":"12","key":"11418_CR38","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1212\/WNL.0000000000003725","volume":"88","author":"G Coarelli","year":"2017","unstructured":"Coarelli G, Diallo A, Thion MS, Rinaldi D, Calvas F, Boukbiza OL et al (2017) Low cancer prevalence in polyglutamine expansion diseases. Neurology 88(12):1114\u20131119","journal-title":"Neurology"},{"issue":"3","key":"11418_CR39","first-page":"209","volume":"7","author":"P McNulty","year":"2018","unstructured":"McNulty P, Pilcher R, Ramesh R, Necuiniate R, Hughes A, Farewell D et al (2018) Reduced cancer incidence in huntington\u2019s disease: analysis in the registry study. J Huntingtons Dis 7(3):209\u2013222","journal-title":"J Huntingtons Dis"},{"issue":"3","key":"11418_CR40","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3233\/JHD-180290","volume":"7","author":"MS Thion","year":"2018","unstructured":"Thion MS, Humbert S (2018) Cancer: from wild-type to mutant huntingtin. J Huntingtons Dis 7(3):201\u2013208","journal-title":"J Huntingtons Dis"},{"issue":"1","key":"11418_CR41","first-page":"72","volume":"32","author":"HC Margolese","year":"2007","unstructured":"Margolese HC, Ferreri F (2007) Management of conventional antipsychotic-induced tardive dyskinesia. J Psychiatry Neurosci 32(1):72","journal-title":"J Psychiatry Neurosci"},{"issue":"4","key":"11418_CR42","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3233\/JHD-210500","volume":"10","author":"N Gavrielov-Yusim","year":"2021","unstructured":"Gavrielov-Yusim N, Barer Y, Martinec M, Siadimas A, Roumpanis S, Furby H et al (2021) Huntington\u2019s disease in Israel: a population-based study using 20 years of routinely-collected healthcare data. J Huntingtons Dis 10(4):469\u2013477","journal-title":"J Huntingtons Dis"},{"issue":"6","key":"11418_CR43","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1212\/CPJ.0000000000001094","volume":"11","author":"E Frank","year":"2021","unstructured":"Frank E, Dyke A, MacKenzie S, Maskwa E, Frank S (2021) Effects of percutaneous endoscopic gastrostomy in patients with Huntington disease. Neurol Clin Pract 11(6):517\u2013520","journal-title":"Neurol Clin Pract"},{"key":"11418_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2021.100470","volume":"16","author":"B Thakor","year":"2021","unstructured":"Thakor B, Jagtap SA, Joshi A (2021) Juvenile Huntington\u2019s disease masquerading as progressive myoclonus epilepsy. Epilepsy Behav Rep 16:100470","journal-title":"Epilepsy Behav Rep"},{"issue":"3","key":"11418_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004962","volume":"4","author":"N Saleh","year":"2009","unstructured":"Saleh N, Moutereau S, Durr A, Krystkowiak P, Azulay JP, Tranchant C et al (2009) Neuroendocrine disturbances in Huntington\u2019s disease. PLoS ONE 4(3):e4962","journal-title":"PLoS ONE"},{"issue":"4","key":"11418_CR46","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3233\/JHD-190372","volume":"8","author":"RY Cheong","year":"2019","unstructured":"Cheong RY, Gabery S, Peters\u00e9n \u00c5 (2019) The role of hypothalamic pathology for non-motor features of Huntington\u2019s disease. J Huntingtons Dis 8(4):375\u2013391","journal-title":"J Huntingtons Dis"},{"key":"11418_CR47","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1111\/ene.15385","volume":"29","author":"H Furby","year":"2022","unstructured":"Furby H, Siadimas A, Rutten-Jacobs L, Rodrigues FB, Wild EJ (2022) Natural history and burden of Huntington\u2019s disease in the UK: a population-based cohort study. Eur J Neurol 29:2249\u20132257","journal-title":"Eur J Neurol"},{"issue":"1","key":"11418_CR48","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/jnnp.66.1.52","volume":"66","author":"T Foroud","year":"1999","unstructured":"Foroud T, Gray J, Ivashina J, Conneally PM (1999) Differences in duration of Huntington\u2019s disease based on age at onset. J Neurol Neurosurg Psychiatry 66(1):52\u201356","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"11418_CR49","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1017\/S0317167100012671","volume":"39","author":"C Rinaldi","year":"2012","unstructured":"Rinaldi C, Salvatore E, Giordano I, De Matteis S, Tucci T, Cinzia VR et al (2012) Predictors of survival in a Huntington\u2019s disease population from southern Italy. Can J Neurol Sci 39(1):48\u201351","journal-title":"Can J Neurol Sci"},{"issue":"5","key":"11418_CR50","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/mdc3.12502","volume":"4","author":"FB Rodrigues","year":"2017","unstructured":"Rodrigues FB, Abreu D, Dam\u00e1sio J, Goncalves N, Correia-Guedes L, Coelho M et al (2017) Survival, mortality, causes and places of death in a European Huntington\u2019s disease prospective cohort. Mov Disord Clin Pract 4(5):737\u2013742","journal-title":"Mov Disord Clin Pract"},{"issue":"1","key":"11418_CR51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3233\/JHD-170270","volume":"7","author":"OK Solberg","year":"2018","unstructured":"Solberg OK, Filkukova P, Frich JC, Feragen KJB (2018) Age at death and causes of death in patients with Huntington disease in Norway in 1986\u20132015. J Huntingtons Dis 7(1):77\u201386","journal-title":"J Huntingtons Dis"},{"key":"11418_CR52","doi-asserted-by":"publisher","first-page":"RRN1293","DOI":"10.1371\/currents.RRN1293","volume":"4","author":"AW Heemskerk","year":"2012","unstructured":"Heemskerk AW, Roos RA (2012) Aspiration pneumonia and death in Huntington\u2019s disease. PLoS Curr. 4:RRN1293","journal-title":"PLoS Curr."},{"issue":"4","key":"11418_CR53","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2217\/nmt-2016-0008","volume":"6","author":"SS Baig","year":"2016","unstructured":"Baig SS, Strong M, Quarrell OW (2016) The global prevalence of Huntington\u2019s disease: a systematic review and discussion. Neurodegener Dis Manag 6(4):331\u2013343","journal-title":"Neurodegener Dis Manag"},{"issue":"1","key":"11418_CR54","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ajhg.2021.12.002","volume":"109","author":"DR Langbehn","year":"2022","unstructured":"Langbehn DR, Registry Investigators of the European Huntington Disease Network (2022) Longer CAG repeat length is associated with shorter survival after disease onset in Huntington disease. Am J Hum Genet 109(1):172\u2013179","journal-title":"Am J Hum Genet"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11418-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11418-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11418-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T23:48:13Z","timestamp":1728172093000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11418-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["11418"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11418-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]},"assertion":[{"value":"17 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AP is funded by research grants from the Swedish Research Council (grant number 2018\/02559), the National Health Services in Sweden as well as the Knut and Alice Wallenberg Foundation as Wallenberg Clinical Scholar (# 2019.0467). DL and SG are salaried employees of Evidera, the consultancy company hired by F. Hoffmann-La Roche Ltd. to perform this work. HF, ALN, SM & RH are all employees of Roche, which has a drugs for Huntington\u2019s Disease under clinical development. HF, SM, ALN and RH are shareholders in F. Hoffmann\u2010La Roche Ltd. PS declares no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Ethical approval was obtained from the Swedish Ethical review board (Etikpr\u00f6vningsmyndigheten; approval number 2020-07037). The Swedish National Board for Health and Welfare (Socialstyrelsen) also conducted a privacy assessment prior to data release.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}